Maze Therapeutics, Inc. (MAZE)
Maze Therapeutics, Inc. (MAZE) from its SEC filings: 2024 revenue $167.5 million, net margin 31%, free cash flow $74.8 million. Insider trades, recent filings and a price chart. Free.
| Exchange | Nasdaq |
| Industry | Biological Products, (No Diagnostic Substances) |
| Revenue (2024) | $167.5 million |
| Net income | $52.2 million |
| Net margin | 31.2% |
| Free cash flow | $74.8 million |
| Diluted EPS | $1.25 |
| Cash | $202.6 million |
| Long-term debt | $39.0 million |
| Share count, 1 year | +27% |
| Fundamentals check | Strong fundamentals |
Source: SEC EDGAR company filings (XBRL), updated 2026-10-23. Education only, not financial advice.